Medical Information Notice
This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or qualified healthcare provider. Read full disclaimer
Trihexyphenidyl
Quick Facts
- Generic Name
- Trihexyphenidyl
- Brand Names
- Artane
- Drug Class
- Anticholinergic
- FDA Approved
- 1949
How It Works
Trihexyphenidyl is an anticholinergic medication that blocks muscarinic acetylcholine receptors (primarily M1) in the central nervous system. In Parkinson's disease, the loss of dopamine disrupts the normal balance between dopamine and acetylcholine in the basal ganglia; anticholinergics help restore this balance by reducing cholinergic overactivity. Trihexyphenidyl is one of the oldest treatments for PD, predating levodopa, and is now used primarily for tremor that does not respond adequately to other medications.
What to Expect as a Patient
Trihexyphenidyl is used primarily for tremor, and you may notice improvement within a few days. However, this medication comes with significant trade-offs, particularly for older adults. Dry mouth, blurred vision, and constipation are very common. Drink plenty of water, use sugar-free candies for dry mouth, and increase dietary fiber for constipation. Memory problems and confusion are particular concerns in patients over 65 — report any changes in thinking to your doctor immediately. Because trihexyphenidyl impairs sweating, you are at increased risk of heat stroke during hot weather. Do not stop abruptly after prolonged use, as this can worsen PD symptoms.
Typical Dosing
Start 1mg/day; increase by 2mg every 3-5 days. Usual dose 6-10mg/day in 3 divided doses. Maximum 15mg/day.
Dosing is individualized by the prescribing physician. The information above is for general reference only.
Common Side Effects
- Dry mouth
- Blurred vision
- Constipation
- Urinary retention
- Memory impairment
- Confusion
Serious Side Effects
Seek medical attention immediately if you experience any of the following:
- Cognitive impairment (especially in patients over 65)
- Confusion and delirium
- Angle-closure glaucoma exacerbation
- Heat stroke (impaired sweating)
- Psychosis
Contraindications
- Narrow-angle glaucoma
- GI or urinary obstruction
- Myasthenia gravis
Food Interactions
Take before or after meals as tolerated. Drink plenty of fluids to counteract dry mouth. Avoid alcohol, which intensifies sedation.
Drug Interactions
The following interactions have been documented with Trihexyphenidyl. Always inform your healthcare provider about all medications you are taking.
Both drugs have anticholinergic properties. Combined use increases anticholinergic burden.
Clinical effects: Confusion, hallucinations, urinary retention, dry mouth, constipation. Risk especially high in elderly.
Management: Use with caution, especially in patients over 65. Monitor for cognitive side effects.
Two anticholinergic agents provide additive anticholinergic burden with no additional therapeutic benefit and greatly increased toxicity risk.
Clinical effects: Severe anticholinergic toxicity: cognitive impairment, confusion, urinary retention, paralytic ileus, hyperthermia, delirium.
Management: Never combine. Choose one anticholinergic only. Both are on the Beers Criteria as potentially inappropriate in elderly.
How Trihexyphenidyl Compares to Alternatives
Trihexyphenidyl and benztropine are the two anticholinergics available for PD. They have similar efficacy and side effect profiles, though benztropine has additional antihistaminic properties that may cause more sedation. Both are substantially less effective than levodopa for overall motor symptom control and are not recommended by the 2025 AAN guideline as preferred therapy for any patient group. Their only remaining niche is tremor-dominant PD in younger patients who have not responded adequately to levodopa or other agents. Compared to all other PD medication classes, anticholinergics have the worst cognitive safety profile.
When Is Trihexyphenidyl Used by Disease Stage?
This medication has a very narrow role in modern PD treatment. It is NOT appropriate for patients over 65, patients with cognitive impairment, or patients with non-tremor-dominant PD. Its use is limited to younger patients (typically under 60) with significant tremor that has not responded to levodopa, dopamine agonists, or MAO-B inhibitors. Even in this narrow population, the cognitive risks must be weighed carefully. Anticholinergics have no role in mid-to-late stage PD where cognitive decline is a concern.
Additional Notes
Primarily used for tremor-dominant PD in younger patients (<65). The AAN guideline notes limited evidence for anticholinergics and recommends against their use in patients over 65 due to cognitive side effects. The American Geriatrics Society Beers Criteria lists all anticholinergics as potentially inappropriate in older adults. Use has declined substantially as newer, better-tolerated medications have become available. A Cochrane review (2003) found only weak evidence supporting anticholinergic use in PD.
Clinical Perspective
Anticholinergics like trihexyphenidyl represent an older era of PD treatment. Before levodopa's introduction in the late 1960s, anticholinergics were the primary pharmacological option. Their use has declined dramatically — and appropriately — as the evidence base for cognitive harm has grown. The Beers Criteria recommendation against anticholinergics in older adults is particularly relevant for PD, where the median age of diagnosis is 62. Nevertheless, for a select minority of younger, cognitively intact patients with prominent, medication-resistant tremor, trihexyphenidyl still has a place. The key is rigorous patient selection and ongoing cognitive monitoring.
This perspective is based on published clinical evidence and guidelines. Individual treatment decisions should always be made with your neurologist.
Sources
- [1]Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson disease. Cochrane Database Syst Rev. 2003;(2):CD003735
- [2]American Geriatrics Society 2023 Updated AGS Beers Criteria. J Am Geriatr Soc. 2023;71(7):2052-2081
- [3]Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-1683
- [4]Tanner CM, Ostrem JL. Parkinson disease. N Engl J Med. 2024;391(5):442-452
- [5]Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D. Use of drugs with anticholinergic effect and impact on cognition in Parkinson disease: a cohort study. J Neurol Neurosurg Psychiatry. 2010;81(2):160-165
Share this article